Perspective Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
CATX$0.86+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except shares and par value data)
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $61,580 | $9,238 |
| Short-term investments | 165,336 | - |
| Accounts receivable, net of allowance for doubtful accounts: $543 and $650 | 116 | 1,165 |
| Prepaid expenses and other current assets | 4,128 | 1,133 |
| Current assets held for sale, discontinued operations | - | 5,301 |
| Total current assets | 231,160 | 16,837 |
| Noncurrent assets: | ||
| Property and equipment, net | 57,321 | 5,576 |
| Right-of-use asset, net | 2,215 | 747 |
| Restricted cash | - | 182 |
| Intangible assets, in-process research and development | 50,000 | 50,000 |
| Goodwill | - | 24,062 |
| Other assets, net | 405 | 487 |
| Total assets | $341,101 | $97,891 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $10,343 | $6,909 |
| Lease liability | 957 | 46 |
| Accrued personnel expenses | 5,478 | 3,588 |
| Note payable | 52 | 49 |
| Deferred Income (Note 3) | 1,400 | - |
| Current liabilities of discontinued operations | - | 5,072 |
| Total current liabilities | 18,230 | 15,664 |
| Noncurrent liabilities: | ||
| Lease liability, net of current portion | 1,428 | 780 |
| Note payable, net of current portion | 1,625 | 1,676 |
| Deferred Income, net of current portion (Note 3) | 26,600 | - |
| Deferred tax liability | 2,495 | 4,592 |
| Other noncurrent liabilities | 55 | - |
| Total liabilities | 50,433 | 22,712 |
| Commitments and contingencies (Note 17) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible; no shares issued | - | - |
| Common stock: $0.001 par value; authorized 750,000,000 shares; issued 70,671,464 and 28,180,985 shares1 | 70 | 28 |
| Additional paid-in capital1 | 522,368 | 227,591 |
| Accumulated other comprehensive loss | (51) | - |
| Accumulated deficit | (231,719) | (152,440) |
| Total stockholders’ equity | 290,668 | 75,179 |
| Total liabilities and stockholders’ equity | $341,101 | $97,891 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.